Drug intelligence / Profile preview

SIM0688

Development stage: Preclinical
Lead developer: Nanjing Zaiming Pharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SIM0688 is a preclinical antibody-drug conjugate (ADC) being developed by Nanjing Zaiming Pharmaceutical, a subsidiary of Simcere Pharmaceutical Group. It is designed to target both B7-H3 (CD276) and the hepatocyte growth factor receptor (cMet), two proteins frequently overexpressed in various solid tumors. By dual-targeting these antigens, SIM0688 aims to deliver a cytotoxic payload specifically to tumor cells, potentially enhancing efficacy and overcoming resistance mechanisms associated with single-target therapies. The drug is currently in the preclinical stage of development for the treatment of solid tumors.

Targets

B7-H3MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on SIM0688.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIM0688.

Explore the full profile